Evidence map›Paper›PMID 41025288›Full record

ArticleAnnals of medicine2025

Predictive value of preoperative CA19-9 and neutrophil-to-lymphocyte ratio for early recurrence in patients with resected pancreatic ductal adenocarcinoma.

Wei-Kang Ye, Xiao-Yu Lin, Si-Qi Liu, Jie Zheng, Jin Wang, Yi-Nong Zhou, Xin-Ming Lei

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei-Kang YeDepartment of Pancreatic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Xiao-Yu LinDepartment of Operating Room, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Si-Qi LiuDepartment of Operating Room, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Jie ZhengDepartment of Pancreatic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Jin WangDepartment of Pancreatic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Yi-Nong ZhouDepartment of Pancreatic Surgery, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.
Xin-Ming LeiDepartment of Gastroenterology, The Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People's Hospital, Quzhou, ZheJiang, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPancreatic ductal adenocarcinoma (PDAC) has a high recurrence rate post-curative surgery. This study aimed to evaluate the combined predictive value of preoperative carbohydrate antigen 19-9 (CA19-9) and neutrophil-to-lymphocyte ratio (NLR) for early recurrence in resected PDAC patients.

methodsThis was a single-centre retrospective study involving 151 patients diagnosed with PDAC. Data on patient demographics, clinical characteristics and preoperative haematological parameters were collected. Early recurrence was defined as recurrence within the first 12 months after surgery. Univariate and multivariate logistic regression analyses were conducted to identify factors associated with early recurrence. Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) analyses were used to assess the diagnostic performance of CA19-9, NLR and their combination.

resultsAmong 151 patients (median follow-up: 21 months), 32.45% (

conclusionThe combination of preoperative CA19-9 and NLR enhances predictive accuracy for early recurrence in PDAC, offering a useful tool for postoperative risk stratification.

Indexed as

CA-19-9 AntigenCarcinoma, Pancreatic DuctalLymphocytesNeoplasm Recurrence, LocalNeutrophilsPancreatic NeoplasmsAdultAgedAged, 80 and overFemaleHumansLymphocyte CountMaleMiddle AgedPredictive Value of TestsPreoperative PeriodCA-19-9 AntigenCa19-9early recurrenceneutrophil-to-lymphocyte ratioPancreatic ductal adenocarcinoma

Identifiers

PMID41025288
PMCPMC12486449

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.